Big Pharmaceuticals Could Enter the Psychedelics Space in 2021

Psychedelics are quickly going mainstream. With US FDA support, several clinical studies, and parts of Europe and the U.S easing restrictions on psilocybin to help treat a range of mental health issues, the story could gain even more momentum in the New Year. Better, big pharmaceutical companies could begin to enter the psychedelic space, repots Wired. In fact, “As patents on many conventional antidepressants begin to expire – and public and regulatory opinion regarding psychedelics is changing – 2021 will be the time that psychedelic therapy casts a spotlight on the limitations of current mental-health care treatments, and highlights a bold alternative.”

In addition, we may soon learn psilocybin could potentially assist in treating eating disorders and obesity. That’s because psilocybin activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.” With the story gaining big momentum, some of the top companies to keep an eye on include NeonMind Biosciences Inc. (CSE: NEON), HAVN Life Sciences Inc. (CSE:HAVN), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), and Cybin Inc. (NEO:CYBN)(OTC:CLXPF).

NeonMind Biosciences Inc. (CSE: NEON), BREAKING NEWS: NeonMind Biosciences Inc. is pleased to announce that its common shares have today commenced trading on the Canadian Securities Exchange under the ticker symbol “NEON”. More information on NeonMind can be found at www.neonmindbiosciences.com.

NeonMind completed its oversubscribed Initial Public Offering on December 30, 2020, for gross proceeds of $4,600,000. NeonMind is a psychedelic drug development company. Its mission is to help people change their lives by changing their minds, through treatment with psychedelics.

NeonMind’s first step is tackling one of the biggest health issues the world is facing right now: obesity. It’s an epidemic that is responsible for 37% of the global burden of disease, according to the National Centre for Biotechnology Information. NeonMind is exploring psilocybin (a complex organic compound found in psychedelic mushrooms) as an innovative treatment approach to weight loss through a preclinical trial. It has hired the University of British Columbia, who has been granted authorization by Health Canada to use Psilocybin in NeonMind’s Preclinical Trial, to test the potential use of Psilocybin to improve eating habits and cause weight loss. The Preclinical Trial started in November 2020 and NeonMind…